Rosetta to Sell $1.4M in Stock

Apr 12, 2012

NEW YORK (GenomeWeb News) – Rosetta Genomics today said that it has signed definitive agreements to sell 8.1 million shares of its stock to certain investors at $0.17 apiece, which would raise $1.4 million for the beleaguered microRNA diagnostics firm.

Rosetta said that the transactions are expected to close on April 17. The proceeds of the offering will be used to fund operations and other general corporate purposes, including the repayment of debt.

Last week, the Israel-based company disclosed that it had enough funds to support its operations only into late May 2012, as it faces a $750,000 payment owed on May 22 to one-time distribution partner Prometheus Laboratories.

Filed under

Gene Editing, Gene Silencing, & CRISPR

RNAi

Rosetta Genomics

Study Examines Insights Gained by Adjunct Trio RNA Sequencing in Complex Pediatric Disease Cases

Researchers in AJHG explore the diagnostic utility of adding parent-child RNA-seq to genome sequencing in dozens of families with complex, undiagnosed genetic disease.

Clinical Genomic Lab Survey Looks at Workforce Needs

Investigators use a survey approach in Genetics in Medicine Open to assess technologist applications, retention, and workforce gaps at molecular genetics and clinical cytogenetics labs in the US.

Study Considers Gene Regulatory Features Available by Sequence-Based Modeling

Investigators in Genome Biology set sequence-based models against observational and perturbation assay data, finding distal enhancer models lag behind promoter predictions.

Genetic Testing Approach Explores Origins of Blastocyst Aneuploidy

Investigators in AJHG distinguish between aneuploidy events related to meiotic missegregation in haploid cells and those involving post-zygotic mitotic errors and mosaicism.